Forward Pharma A/S

Forward Pharma A/S

Forward Pharma A/S

Overview
Date Founded

2005

Headquarters

Østergade 24A,1st Floor,Copenhagen, Capital Region 1100

Type of Company

Public

Employees (Worldwide)

13

Industries

Pharmaceuticals
Biotechnology

Company Description

Forward Pharma is a biopharmaceutical company which engages in the research and production of medicinal treatment for multiple sclerosis and psoriasis. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.

Executives & Employees

Chief Executive Officer

Vice President, Finance & Controller, Forward Pharma USA, LLC

Board of Directors

Partner & Co-Founder at Nordic Biotech Advisors ApS

Partner at Rosetta Capital Ltd.

Partner at East West Capital Partners Pte Ltd.

Paths to Forward Pharma A/S
Potential Connections via
Relationship Science
You
Forward Pharma A/S
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Recent Transactions
Details Hidden

Forward Pharma A/S issued American Depositary Shares (ADS)

Advisors & Consultants
Scientific Advisor

Member, Clinical Advisory Board at Vascular Biogenics Ltd.

Scientific Advisor

Director of the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Medical Center, Inc.

Scientific Advisor

Neurology Director at Fondazione San Raffaele del Monte Tabor-Milano

Clients

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Key Stats and Financials As of 2016
Market Capitalization
$109M
Total Enterprise Value
$566M
Earnings Per Share
$-0.71
Net Profit
$-33.2M
EBITDA
$-55.2M
Total Debt
$0
Total Equity
$157M
TEVNet Income
-17.02x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Revenue
$0
Investors
Details Hidden

Partner & Co-Founder at Nordic Biotech Advisors ApS

Details Hidden

NBA is a long-term investor. Their investment strategy focuses on fast-growing seed and early-stage biotech firms primarily based in Europe. Some of their portfolio firms are also running late-stage clinical programs. They target unlisted firms which have rights to promising drugs under development. They are also involved with spin-out transactions. They consider special investment opportunities worldwide.NBA strives to maximize the value of their portfolio firms. They generally take majority stakes. They are active owners. They are involved in their portfolio firms' Boards, strategy development and financing. They seek to position their firms for major public and private offerings, M&A transactions as well as corporate partnerships.Within the biotechnology and pharmaceutical areas, they have invested in technology that enhances small molecule bio-availability and related clinical efficacy and side-effect parameters, drug development for allergic diseases with a mature pipeline of clinical development projects based on oral delivery of allergens, drugs based on ghrelin and GLP-1 for various indications, drugs for bone and cartilage diseases such as most notably osteoporosis, immunomodulatory drugs for the treatment of a range of common disorders as well as the development of peptide therapeutics for various disorders.

Details Hidden

Rosetta is an active manager investing in early and mid-stage growth companies in biotechnology-related sectors. The firm makes both direct equity investments and secondary investments. They also invest in acquisition financing and spin-off transactions.

Suppliers
Competitors
Celgene Corp. Pharmaceuticals - Summit, New Jersey

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy